| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30055083 | HIV | ENSG00000093010.15 | protein_coding | COMT | No | No | 1312 | P21964 |
| TVIS20014702 | HPV | ENSG00000093010.15 | protein_coding | COMT | No | No | 1312 | P21964 |
| TVIS20014703 | HPV | ENSG00000093010.15 | protein_coding | COMT | No | No | 1312 | P21964 |
| TVIS20014704 | HPV | ENSG00000093010.15 | protein_coding | COMT | No | No | 1312 | P21964 |
| TVIS20025997 | HPV | ENSG00000093010.15 | protein_coding | COMT | No | No | 1312 | P21964 |
| TVIS20034287 | HPV | ENSG00000093010.15 | protein_coding | COMT | No | No | 1312 | P21964 |
| TVIS20014705 | HPV | ENSG00000093010.15 | protein_coding | COMT | No | No | 1312 | P21964 |
| TVIS20014706 | HPV | ENSG00000093010.15 | protein_coding | COMT | No | No | 1312 | P21964 |
| TVIS20014712 | HPV | ENSG00000093010.15 | protein_coding | COMT | No | No | 1312 | P21964 |
| TVIS20014713 | HPV | ENSG00000093010.15 | protein_coding | COMT | No | No | 1312 | P21964 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | COMT |
|---|---|
| DrugBank ID | DB00494 |
| Drug Name | Entacapone |
| Target ID | BE0002089 |
| UniProt ID | P21964 |
| Regulation Type | inhibitor |
| PubMed IDs | 11752352; 11440283; 10981253; 10439935; 11939936; 12876237; 12538800; 11873938; 10882160; 9808337 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Najib J: Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771.@@Chong BS, Mersfelder TL: Entacapone. Ann Pharmacother. 2000 Sep;34(9):1056-65.@@Holm KJ, Spencer CM: Entacapone. A review of its use in Parkinson's disease. Drugs. 1999 Jul;58(1):159-77.@@Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M: Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002 Apr;105(4):245-55.@@Brooks DJ, Sagar H: Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071-9.@@Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506.@@Tai CH, Wu RM: Catechol-O-methyltransferase and Parkinson's disease. Acta Med Okayama. 2002 Feb;56(1):1-6.@@Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50.@@Ruottinen HM, Rinne UK: COMT inhibition in the treatment of Parkinson's disease. J Neurol. 1998 Nov;245(11 Suppl 3):P25-34. |
| Groups | Approved; Investigational |
| Direct Classification | Hydroxycinnamic acids and derivatives |
| SMILES | CCN(CC)C(=O)C(=CC1=CC(=C(O)C(O)=C1)[N+]([O-])=O)C#N |
| Pathways | |
| PharmGKB | PA164748726 |
| ChEMBL | CHEMBL953 |
